Future Medical Device Companies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Future Medical Device Companies

STXS 2.910

-0.3%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: dr.praveen who wrote (12)	3/8/2007 1:43:03 PM
From: tewdwr	of 136

see this from Nature - Clinical Practice : Cardiovascular Medicine which includes limitations of OCT limited to a saline flush at imaging site to clear obscuring red blood cells and a possible transient ischemic episode that may not be well tolerated. OCT over IVUS sometime in the future, BUT as of 2005 the risks and discomfort of OCT procedure to patient may outweigh the benefit. nature.com "Current limitations of oct OCT needs a blood-free imaging field because red blood cells scatter light. The required saline flushes limit scan times to approximately 2 s per flush, and restrict the length of vessel segments that can be imaged. Other new technologies employing balloon occlusion for a static saline column, or continuous saline flush, may allow for scanning of longer vessel segments. This approach results in transient ischemia, however, which might not be tolerated. Conversely, the presence of side branches could affect clearing of the blood field. Index matching is another possible solution and is based on the hypothesis that the predominant source of scattering in blood is the difference in refractive index between the cytoplasm of erythrocytes and serum. Hence, setting the refractive index of serum at a value similar to the cytoplasm could substantially reduce scattering.24 A possible future alternative approach is isovolumic replacement of blood with an optically transparent hemoglobin-based blood substitute, which has been tested in mouse myocardium.25"

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next